France’s Sanofi has disappointed investors again with its outlook for diabetes sales, and earnings. Novo Nordisk is better placed but the risks are rising.
WSJ.com: Heard on the Street, Wall Street Journal: Markets: Heard on the Street
Tue, 11/10/2015 - 3:36am
France’s Sanofi has disappointed investors again with its outlook for diabetes sales, and earnings. Novo Nordisk is better placed but the risks are rising.